Polyphenols from green tea and pomegranate for prevention of prostate cancer

References

• Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics. CA Cancer J Clin 2006; 56: 106–130
   PubMed Web of Science ®Google Scholar
• Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, Boone CW, Kopelovich L, Hawk ET, Lieberman R, Lawrence JA, Ali I, Viner JL, Sigman CC. Progress in cancer chemoprevention: Development of diet-derived chemopreventive agents. J Nutr 2000; 130: 467S–471S
   PubMed Web of Science ®Google Scholar
• Boone CW, Bacus JW, Bacus JV, Steele VE, Kelloff GJ. Properties of intraepithelial neoplasia relevant to the development of cancer chemopreventive agents. J Cell Biochem 1997; 28–29: 1–20
   Google Scholar
• Sporn MB, Liby KT. Cancer chemoprevention: Scientific promise, clinical uncertainty. Nat Clin Pract Oncol 2005; 2: 518–525
   PubMedGoogle Scholar
• Sporn MB, Suh N. Chemoprevention of cancer. Carcinogenesis 2000; 21: 525–530
   PubMed Web of Science ®Google Scholar
• Boone CW, Kelloff GJ, Steele VE. Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy. Cancer Res 1992; 52: 1651–1659
   PubMed Web of Science ®Google Scholar
• Siddiqui IA, Afaq F, Adhami VM, Ahmad N, Mukhtar H. Antioxidants of the beverage tea in promotion of human health. Antioxid Redox Signal 2004; 6: 571–582
   PubMed Web of Science ®Google Scholar
• Saleem M, Adhami VM, Siddiqui IA, Mukhtar H. Tea beverage in chemoprevention of prostate cancer: A mini-review. Nutr Cancer 2003; 47: 13–23
   PubMed Web of Science ®Google Scholar
• Adhami VM, Ahmad N, Mukhtar H. Molecular targets for green tea in prostate cancer prevention. J Nutr 2003; 133: 2417S–2424S
   PubMed Web of Science ®Google Scholar
• Mukhtar H, Ahmad N. Green tea in chemoprevention of cancer. Toxicol Sci 1999; 52: 111–117
   PubMed Web of Science ®Google Scholar
• Siddiqui IA, Adhami VM, Saleem M, Mukhtar H. Beneficial effects of tea and its polyphenols against prostate cancer. Mol Nutr Food Res 2006; 50: 130–143
   PubMed Web of Science ®Google Scholar
• Klein EA. Chemoprevention of prostate cancer. Crit Rev Oncol Hematol 2005; 54: 1–10
   PubMed Web of Science ®Google Scholar
• Kelloff GJ, Lieberman R, Steele VE, Boone CW, Lubet RA, Kopelovitch L, Malone WA, Crowell JA, Sigman CC. Chemoprevention of prostate cancer: Concepts and strategies. Eur Urol 1999; 35: 342–350
   PubMed Web of Science ®Google Scholar
• Sonn GA, Aronson W, Litwin MS. Impact of diet on prostate cancer: A review. Prostate Cancer Prostatic Dis 2005; 8: 304–310
   PubMed Web of Science ®Google Scholar
• Sim HG, Cheng CW. Changing demography of prostate cancer in Asia. Eur J Cancer 2005; 41: 834–845
   PubMed Web of Science ®Google Scholar
• Michaud DS, Augustsson K, Rimm EB, Stampfer MJ, Willet WC, Giovannucci E. A prospective study on intake of animal products and risk of prostate cancer. Cancer Causes Control 2001; 12: 557–567
   PubMed Web of Science ®Google Scholar
• Platz EA, Leitzmann MF, Michaud DS, Willett WC, Giovannucci E. Interrelation of energy intake, body size, and physical activity with prostate cancer in a large prospective cohort study. Cancer Res 2003; 63: 8542–8548
   PubMed Web of Science ®Google Scholar
• Schuurman AG, Goldbohm RA, Brants HA, van den Brandt PA. A prospective cohort study on intake of retinol, vitamins C and E, and carotenoids and prostate cancer risk [Netherlands]. Cancer Causes Control 2002; 13: 573–582
   PubMed Web of Science ®Google Scholar
• Malik A, Mukhtar H. Prostate cancer prevention through pomegranate fruit. Cell Cycle 2006; 5: 371–373
   PubMed Web of Science ®Google Scholar
• Malik A, Afaq F, Sarfaraz S, Adhami VM, Syed DN, Mukhtar H. Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci USA 2005; 102: 14813–14818
   PubMed Web of Science ®Google Scholar
• Yang CS, Wang ZY. Tea and cancer. J Natl Cancer Inst 1993; 85: 1038–1049
   PubMed Web of Science ®Google Scholar
• Yang CS, Liao J, Yang GY, Lu G. Inhibition of lung tumorigenesis by tea. Exp Lung Res 2005; 31: 135–144
   PubMed Web of Science ®Google Scholar
• Katiyar SK, Ahmad N, Mukhtar H. Green tea and skin. Arch Dermatol 2000; 136: 989–994
   PubMed Web of Science ®Google Scholar
• Inoue M, Tajima K, Hirose K, Hamajima N, Takezaki T, Kuroishi T, Tominaga S. Tea and coffee consumption and the risk of digestive tract cancers: Data from a comparative case-referent study in Japan. Cancer Causes Control 1998; 9: 209–216
   PubMed Web of Science ®Google Scholar
• Klaunig JE. Chemopreventive effects of green tea components on hepatic carcinogenesis. Prev Med 1992; 21: 510–519
   PubMed Web of Science ®Google Scholar
• Yu GP, Hsieh CC, Wang LY, Yu SZ, Li XL, Jin TH. Green-tea consumption and risk of stomach cancer: A population-based case-control study in Shanghai, China. Cancer Causes Control 1995; 6: 532–538
   PubMed Web of Science ®Google Scholar
• Seely D, Mills EJ, Wu P, Verma S, Guyatt GH. The effects of green tea consumption on incidence of breast cancer and recurrence of breast cancer: A systematic review and meta-analysis. Integr Cancer Ther 2005; 4: 144–155
   PubMedGoogle Scholar
• Wilding G. Endocrine control of prostate cancer. Cancer Surv 1995; 23: 43–62
   PubMedGoogle Scholar
• Lipsett MB. Estrogen use and cancer risk. J Am Med Assoc 1977; 237: 1112–1115
   PubMed Web of Science ®Google Scholar
• Liao S, Hiipakka RA. Selective inhibition of steroid 5 alpha-reductase isozymes by tea epicatechin-3-gallate and epigallocatechin-3-gallate. Biochem Biophys Res Commun 1995; 214: 833–838
   PubMed Web of Science ®Google Scholar
• Ren F, Zhang S, Mitchell SH, Butler R, Young CY. Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene 2000; 19: 1924–1932
   PubMed Web of Science ®Google Scholar
• Gupta S, Ahmad N, Mukhtar H. Prostate cancer chemoprevention by green tea. Seminars Urol Oncol 1999; 17: 70–76
   PubMedGoogle Scholar
• Mohan RR, Challa A, Gupta S, Bostwick DG, Ahmad N, Agarwal R, Marengo SR, Amini SB, Paras F, MacLennan GT, Resnick MI, Mukhtar H. Overexpression of ornithine decarboxylase in prostate cancer and prostatic fluid in humans. Clin Cancer Res 1999; 5: 143–147
   PubMed Web of Science ®Google Scholar
• Bettuzzi S, Davalli P, Astancolle S, Carani C, Madeo B, Tampieri A, Corti A. Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens. Cancer Res 2000; 60: 28–34
   PubMed Web of Science ®Google Scholar
• Gupta S, Ahmad N, Mohan RR, Husain MM, Mukhtar H. Prostate cancer chemoprevention by green tea: In vitro and in vivo inhibition of testosterone-mediated induction of ornithine decarboxylase. Cancer Res 1999; 59: 2115–2120
   PubMed Web of Science ®Google Scholar
• Martin KR. Targeting apoptosis with dietary bioactive agents. Exp Biol Med 2006; 231: 117–129
   PubMed Web of Science ®Google Scholar
• Ahmad N, Feyes DK, Nieminen AL, Agarwal R, Mukhtar H. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst 1997; 89: 1881–1886
   PubMed Web of Science ®Google Scholar
• Paschka AG, Butler R, Young CY. Induction of apoptosis in prostate cancer cell lines by the green tea component, (-)-epigallocatechin-3-gallate. Cancer Lett 1998; 130: 1–7
   PubMed Web of Science ®Google Scholar
• Gupta S, Ahmad N, Nieminen AL, Mukhtar H. Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol Appl Pharmacol 2000; 164: 82–90
   PubMed Web of Science ®Google Scholar
• Gupta S, Hussain T, Mukhtar H. Molecular pathway for (-)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem Biophys 2003; 410: 177–185
   PubMed Web of Science ®Google Scholar
• Hastak K, Gupta S, Ahmad N, Agarwal MK, Agarwal ML, Mukhtar H. Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene 2003; 22: 4851–4859
   PubMed Web of Science ®Google Scholar
• Gupta S, Hastak K, Afaq F, Ahmad N, Mukhtar H. Essential role of caspases in epigallocatechin-3-gallate-mediated inhibition of nuclear factor kappa B and induction of apoptosis. Oncogene 2004; 23: 2507–2522
   PubMed Web of Science ®Google Scholar
• Hastak K, Agarwal MK, Mukhtar H, Agarwal ML. Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate. FASEB J 2005; 19: 789–791
   PubMed Web of Science ®Google Scholar
• Hochstrasser M. Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol 1995; 7: 215–223
   PubMed Web of Science ®Google Scholar
• Dou QP, Li B. Proteasome inhibitors as potential novel anticancer agents. Drug Resistance Updates 1999; 2: 215–223
   PubMed Web of Science ®Google Scholar
• Nam S, Smith DM, Dou QP. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 2001; 276: 13322–13330
   PubMed Web of Science ®Google Scholar
• Smith DM, Wang Z, Kazi A, Li LH, Chan TH, Dou QP. Synthetic analogs of green tea polyphenols as proteasome inhibitors. Mol Med 2002; 8: 382–392
   PubMed Web of Science ®Google Scholar
• Wang SI, Mukhtar H. Gene expression profile in human prostate LNCaP cancer cells by epigallocatechin-3-gallate. Cancer Lett 2002; 182: 43–51
   PubMed Web of Science ®Google Scholar
• Livneh E, Fishman DD. Linking protein kinase C to cell-cycle control. Eur J Biochem 1997; 248: 1–9
   PubMedGoogle Scholar
• Fishman DD, Segal S, Livneh E. The role of protein kinase C in G1 and G2/M phases of the cell cycle. Int J Oncol 1998; 12: 181–186
   PubMed Web of Science ®Google Scholar
• Liao S, Umekita Y, Guo J, Kokontis JM, Hiipakka RA. Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Cancer Lett 1995; 96: 239–243
   PubMed Web of Science ®Google Scholar
• Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A, Rath M. In vivo antitumor effect of ascorbic acid, lysine, proline and green tea extract on human prostate cancer PC-3 xenografts in nude mice: Evaluation of tumor growth and immunohistochemistry. In Vivo 2005; 19: 179–183
   PubMed Web of Science ®Google Scholar
• Siddiqui IA, Zaman N, Aziz MH, Reagan-Shaw SR, Sarfaraz S, Adhami VM, Ahmad N, Raisuddin S, Mukhtar H. Inhibition of CWR22R{nu}1 tumor growth and PSA secretion in athymic nude mice by green and black teas. Carcinogenesis 2006; 27: 833–839
   PubMed Web of Science ®Google Scholar
• Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg NM. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996; 56: 4096–4102
   PubMed Web of Science ®Google Scholar
• Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 1997; 57: 4687–4691
   PubMed Web of Science ®Google Scholar
• Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by I oral infusion of green tea polyphenols. Proc Natl Acad Sci USA 2001; 98: 10350–10355
   PubMed Web of Science ®Google Scholar
• Adhami VM, Siddiqui IA, Ahmad N, Gupta S, Mukhtar H. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res 2004; 64: 8715–8722
   PubMed Web of Science ®Google Scholar
• Caporali A, Davalli P, Astancolle S, D'Arca D, Brausi M, Bettuzzi S, Corti A. The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression. Carcinogenesis 2004; 25: 2217–2224
   PubMed Web of Science ®Google Scholar
• Boyle P, Severi G. Epidemiology of prostate cancer chemoprevention. Eur Urol 1999; 35: 370–376
   PubMedGoogle Scholar
• Blot WJ, Chow WH, McLaughlin JK. Tea and cancer: A review of the epidemiological evidence. Eur J Cancer Prev 1996; 5: 425–438
   PubMed Web of Science ®Google Scholar
• Adlercreutz H. Western diet and Western diseases: Some hormonal and biochemical mechanisms and associations. Scand J Clin Lab Invest Suppl 1990; 201: 3–23
   PubMedGoogle Scholar
• Denis L, Morton MS, Griffiths K. Diet and its preventive role in prostatic disease. Eur Urol 1999; 35: 377–387
   PubMed Web of Science ®Google Scholar
• Angwafo FF. Migration and prostate cancer: An international perspective. J Natl Med Assoc 1998; 90: S720–S723
   PubMed Web of Science ®Google Scholar
• Heilbrun LK, Nomura A, Stemmermann GN. Black tea consumption and cancer risk: A prospective study. Br J Cancer 1986; 54: 677–683
   PubMed Web of Science ®Google Scholar
• Jain MG, Hislop GT, Howe GR, Burch JD, Ghadirian P. Alcohol and other beverage use and prostate cancer risk among Canadian men. Int J Cancer 1998; 78: 707–711
   PubMed Web of Science ®Google Scholar
• Jian L, Xie LP, Lee AH, Binns CW. Protective effect of green tea against prostate cancer: A case-control study in southeast China. Int J Cancer 2004; 108: 130–135
   PubMed Web of Science ®Google Scholar
• Jatoi A, Ellison N, Burch PA, Sloan JA, Dakhil SR, Novotny P, Tan W, Fitch TR, Rowland KM, Young CY, Flynn PJ. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003; 97: 1442–1446
   PubMed Web of Science ®Google Scholar
• Choan E, Segal R, Jonker D, Malone S, Reaume N, Eapen L, Gallant V. A prospective clinical trial of green tea for hormone refractory prostate cancer: An evaluation of the complementary/alternative therapy approach. Urol Oncol 2005; 23: 108–113
   PubMed Web of Science ®Google Scholar
• Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: A preliminary report from a one-year proof-of-principle study. Cancer Res 2006; 66: 1234–1240
   PubMed Web of Science ®Google Scholar
• Longtin R. The pomegranate: Nature's power fruit?. J Natl Cancer Inst 2003; 95: 346–348
   PubMedGoogle Scholar
• Schubert SY, Lansky EP, Neeman I. Antioxidant and eicosanoid enzyme inhibition properties of pomegranate seed oil and fermented juice flavonoids. J Ethnopharmacol 1999; 66: 11–17
   PubMed Web of Science ®Google Scholar
• Gil MI, Tomas-Barberan FA, Hess-Pierce B, Holcroft DM, Kader AA. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J Agric Food Chem 2000; 48: 4581–4589
   PubMed Web of Science ®Google Scholar
• Noda Y, Kaneyuki T, Mori A, Packer L. Antioxidant activities of pomegranate fruit extract and its anthocyanidins: Delphinidin, cyanidin, and pelargonidin. J Agric Food Chem 2002; 50: 166–171
   PubMed Web of Science ®Google Scholar
• Kim ND, Mehta R, Yu W, Neeman I, Livney T, Amichay A, Poirier D, Nicholls P, Kirby A, Jiang W, Mansel R, Ramachandran C, Rabi T, Kaplan B, Lansky E. Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res Treat 2002; 71: 203–217
   PubMed Web of Science ®Google Scholar
• Toi M, Bando H, Ramachandran C, Melnick SJ, Imai A, Fife RS, Carr RE, Oikawa T, Lansky EP. Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo. Angiogenesis 2003; 6: 121–128
   PubMedGoogle Scholar
• Lansky EP, Harrison G, Froom P, Jiang WG. Pomegranate (Punica granatum) pure chemicals show possible synergistic inhibition of human PC-3 prostate cancer cell invasion across Matrigel. Invest New Drugs 2005; 23: 121–122
   PubMed Web of Science ®Google Scholar
• Lansky EP, Jiang W, Mo H, Bravo L, Froom P, Yu W, Harris NM, Neeman I, Campbell MJ. Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions. Invest New Drugs 2005; 23: 11–20
   PubMed Web of Science ®Google Scholar
• Albrecht M, Jiang W, Kumi-Diaka J, Lansky EP, Gommersall LM, Patel A, Mansel RE, Neeman I, Geldof AA, Campbell MJ. Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. J Med Food 2004; 7: 274–283
   PubMed Web of Science ®Google Scholar
• Seeram NP, Adams LS, Henning SM, Niu Y, Zhang Y, Nair MG, Heber D. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem 2005; 16: 360–367
   PubMed Web of Science ®Google Scholar
• Pantuck AJ, Zomorodian N, Belldegrun AS. Phase-II study of pomegranate juice for men with prostate cancer and increasing PSA. Curr Urol Rep 2006; 7(1)7, Jan
   PubMedGoogle Scholar
• Thomas R, Kim MH. Epigallocatechin gallate inhibits HIF-1alpha degradation in prostate cancer cells. Biochem Biophys Res Commun 2005; 334: 543–548
   PubMed Web of Science ®Google Scholar
• Hussain T, Gupta S, Adhami VM, Mukhtar H. Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells. Int J Cancer 2005; 113: 660–669
   PubMed Web of Science ®Google Scholar
• Pezzato E, Sartor L, Dell'Aica I, Dittadi R, Gion M, Belluco C, Lise M, Garbisa S. Prostate carcinoma and green tea: PSA-triggered basement membrane degradation and MMP-2 activation are inhibited by (-)epigallocatechin-3-gallate. Int J Cancer 2004; 112(5)787–792
   PubMed Web of Science ®Google Scholar
• Sartor L, Pezzato E, Dona M, Dell'Aica I, Calabrese F, Morini M, Albini A, Garbisa S. Prostate carcinoma and green tea: (-)epigallocatechin-3-gallate inhibits inflammation-triggered MMP-2 activation and invasion in murine TRAMP model. Int J Cancer 2004; 112(5)823–829, Dec
   PubMed Web of Science ®Google Scholar
• Brusselmans K, De Schrijver E, Heyns W, Verhoeven G, Swinnen JV. Epigallocatechin-3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells. Int J Cancer 2003; 106(6)856–862, Oct
   PubMed Web of Science ®Google Scholar
• Siddiqui IA, Adhami VM, Afaq F, Ahmad N, Mukhtar H. Modulation of phosphatidylinositol-3-kinase/protein kinase B- and mitogen-activated protein kinase-pathways by tea polyphenols in human prostate cancer cells. J Cell Biochem 2004; 91(2)232–242
   PubMed Web of Science ®Google Scholar
• Mukhtar H, Ahmad N. Cancer chemoprevention: Future holds in multiple agents. Toxicol Appl Pharmacol 1999; 158(3)207–210, Aug
   PubMed Web of Science ®Google Scholar